Monday, June 01, 2026
In Detail Full day, Monday, June 01, 2026, Timezone: America/Chicago
CMS releases Medicaid work requirements guidance for states
Rebecca Pifer Parduhn / healthcaredive - The highly anticipated interim final rule weighs in on key issues for states hustling to operationalize work requirements before the 2027 deadline. But there’s still some gray area — and lots of critics.
AI Summary: The Centers for Medicare & Medicaid Services released a national framework for implementing Medicaid work requirements, giving states guidance on eligibility, reporting and enforcement. The directive outlines guardrails and operational expectations while leaving significant discretion to states, prompting debate over access, administrative burden and potential gaps in coverage during rollout.
Massachusetts sues UnitedHealthcare over alleged $100M in fraudulent Medicaid payments
Elizabeth Casolo / beckershospitalreview - Massachusetts filed a lawsuit against UnitedHealthcare, accusing the insurer of retaining more than $100 million in fraudulent Medicaid payments. The May 29 complaint, filed in a state court, focuses on UnitedHealthcare’s role as a contractor for “Senior …
AI Summary: The Massachusetts attorney general filed a civil suit accusing UnitedHealthcare of submitting improper Medicaid payments, alleging roughly $100 million in fraudulent claims tied to managed‑care contracts. The action seeks recovery and oversight remedies as state regulators press insurers on billing practices, underscoring growing scrutiny of Medicaid managed‑care arrangements.
Zanidatamab Plus Chemotherapy Prolongs PFS Over Trastuzumab Plus Chemotherapy in Patients with HER2-positive Advanced Gastro-Oesophageal Adenocarcinoma
esmo - Findings from the HERIZON-GEA-01 study
AI Summary: A phase 3 readout from the HERIZON‑GEA‑01 program shows zanidatamab plus chemotherapy prolongs progression‑free survival compared with trastuzumab plus chemotherapy in HER2‑positive advanced gastro‑oesophageal adenocarcinoma. The data, now published and debated at ASCO, also probes whether adding anti‑PD‑1 therapy (tislelizumab) meaningfully changes outcomes — promising for a tough cancer, if you like incremental revolutions.
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
Martin Wermke / nature - Nature Medicine, Published online: 31 May 2026; doi:10.1038/s41591-026-04455-xAs presented at the 2026 ASCO Annual Meeting, in a prespecified interim analysis of a phase 1a trial of IMA401—a new bispecific TCR-based T cell engager that binds a MAGE-A4/MAG…
AI Summary: A phase 1 trial of a TCR‑based bispecific T‑cell engager targeting MAGE‑A4 and MAGE‑A8 demonstrated early anti‑tumor activity in recurrent or refractory solid tumors, with an acceptable safety profile in dose‑finding cohorts. These results revive interest in targeting intracellular cancer antigens via T‑cell redirection, nudging immunotherapy beyond familiar checkpoint territory.
One-time gene editing treatment lowers 'bad' cholesterol by up to 62%
medicalxpress - Patients in London have received a pioneering new gene editing therapy that lowers "bad" cholesterol after a single infusion, as part of a study involving UCL scientists.
AI Summary: Early clinical data show a one‑time gene‑editing infusion can reduce LDL cholesterol by as much as 62% in patients with severe hypercholesterolemia. The approach, still experimental, produced large lipid drops with early safety signals, hinting at a possible future one‑and‑done therapy for high‑risk cardiovascular patients — pending larger trials and careful long‑term follow‑up.
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Healthcare Finance, Behavioral Health, Long COVID, CDC and look for the RSS link.
StackHealth Time Machine
More StackHealth